NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Nucleophosmin (NPM1) mutations are common in acute myeloid leukemia and are associated with high remission rates and prolonged survival with intensive chemotherapy. NPM1 mutations are rare in myelodysplastic syndromes (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN), and the clinical o...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: Montalban-Bravo, Guillermo, Kanagal-Shamanna, Rashmi, Sasaki, Koji, Patel, Keyur, Ganan-Gomez, Irene, Jabbour, Elias, Kadia, Tapan, Ravandi, Farhad, DiNardo, Courtney, Borthakur, Gautham, Takahashi, Koichi, Konopleva, Marina, Komrokji, Rami S., DeZern, Amy, Kuzmanovic, Teodora, Maciejewski, Jaroslaw, Pierce, Sherry, Colla, Simona, Sekeres, Mikkael A., Kantarjian, Hagop, Bueso-Ramos, Carlos, Garcia-Manero, Guillermo
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2019
Sujets:
Myeloid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6436014/
https://ncbi.nlm.nih.gov/pubmed/30902805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018026989
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires